Drug intelligence / Profile preview

LY041001

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Inhalation

Overview

LY041001 is a code name used for different formulations of human insulin. These formulations include U-500 insulin, a concentrated form of human regular insulin, and human insulin inhalation powder (HIIP), an inhaled form of insulin. It has been investigated in clinical trials for the treatment of both Type 1 and Type 2 Diabetes Mellitus. Human insulin functions as a hormone that regulates glucose metabolism in the body.

Other names: U-500 InsulinU500 InsulinU 500 Insulinhuman insulin inhalation powderhuman regular U-500 insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on LY041001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY041001.

Explore the full profile